Hikma shares higher as company resumes launch of generic Advair Diskus



© Reuters.

By Samuel Indyk

Investing.com – Hikma Pharmaceuticals (LON:) shares have jumped towards the top of the on Wednesday after the company announced it has resumed the launch of its generic version of GlaxoSmithKline’s Advair Diskus.

The news follows US Food and Drug Administration (FDA) approval of an amendment Hikma submitted to its Abbreviated New Drug Application in January 2021.

Advair Diskus is a prescription medicine used to treat asthma in patients four years and older.

“We appreciate the FDA’s timely review and approval of our amendment and are now immediately resuming the launch of our high quality, substitutable generic version of Advair Diskus,” Hikma CEO Siggi Olafsson said in a statement. “We are very pleased to improve availability of this critical medicine for patients and healthcare providers in the US.”

At 09:20BST Hikma Pharmaceuticals shares were trading higher by 2.6% at £24.40 per share.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

READ  Ex-Goldman Bankers Leissner, Ng Banned From Industry by Fed





READ SOURCE

LEAVE A REPLY

Please enter your comment!
Please enter your name here